Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)

Prior treatment

• Concomitant oral or intravenous therapy with CYP2C19 medium or strong inhibitors.
• Concern for inability of the patient to comply with study procedures and/or followup (eg, alcohol or drug abuse).

Other illness

• Planned major cardiac or non-cardiac surgery during the study period.
• Subjects with renal failure who required or anticipated dialysis during the study period.
• Patients with:
  • A history of intracranial bleed or ischemic stroke at any time.
  • A central nervous system tumor or intracranial vascular abnormality (eg, aneurysm, arteriovenous malformation) at any time.
  • Intracranial or spinal cord surgery within 5 years.
• Any condition which in the opinion of the investigator would make it unsafe or unsuitable for the patient to participate in this study (eg, active malignancy other than squamous cell or basal cell skin cancer).

Lab values

• Known severe liver disease(ALT/AST is 3 times above normal).
• Platelet count \<50×10\^9/L.

Other

• \- Subjects who meet any one of the following criteria are excluded from the study:
• Planned to use of ADP receptor blockers (eg, clopidogrel, ticagrelor, and ticlopidine), dipyridamole, or cilostazol.
• Contraindication to ADP receptor blockers or aspirin.
• Planned to use anticoagulants during the study period.
• Planned coronary, cerebrovascular, or peripheral arterial revascularization during the study period.
• Pregnancy or lactation or planned to pregnant during the study period.
• Life expectancy \< 1 year.
• Participation in another clinical study and did not reach the major endpoint.
• Involvement in the planning and/or conduct of the study.

• The enrolled subjects must meet all of the following criteria:
  • Aged 18-75 years old (inclusive).
  • Patients with MVD who underwent DES implantation for 12 months.
  • Patients have been treated with aspirin and can tolerant of aspirin at doses of 75-150 mg/day as maintenance therapy during the study period.
  • Patients have signed informed consent.